Artesunate suppositories work with artemisinin suppositories in severe malaria was conducted in Viet Nam in the early 1990s, and clinical trials of rectal artesunate followed by mefloquine treatment in moderately severe malaria were conducted in the mid-1990s in Thailand. A major placebo-controlled clinical trial published in 2009 found that "if patients with severe malaria cannot be treated orally and access to injections will take several hours, a single inexpensive artesunate [rectal] suppository at the time of referral substantially reduces the risk of death or permanent disability." Artesunate suppositories Artesunate suppositories are used for the treatment of malaria. Artesunate is an antimalarial water-soluble
Mefloquine ears. It is therefore not recommended in people with a history of mental health problems or epilepsy. Common side effects include vomiting, diarrhea, headaches, and a rash. It is not recommended in pregnancy unless other options are not available. It should not be used during breast feeding. Mefloquine was developed by the United States Army in the 1970s and came into use in the mid 1980s. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale price in the